🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 21 of 28

  1. PRT543

    Prelude Therapeutics Inc

    Relapsed/Refractory Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  2. PRT7732

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  3. PRT811

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  4. PSA/IL-2/GM-CSF

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 mab active

    1 trial

  5. PTC299

    PTC THERAPEUTICS, INC.

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  6. PTC299

    PTC THERAPEUTICS, INC.

    Leukemia, Myeloid, Acute

    phase 1 small molecule terminated

    1 trial

  7. PTC299

    PTC THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  8. PTC596

    PTC THERAPEUTICS, INC.

    Cancer

    phase 1 small molecule completed

    1 trial

  9. PV-10 (10% rose bengal disodium)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Cancer Metastatic to the Liver

    phase 1 small molecule active

    1 trial

  10. PV-10 (rose bengal disodium 10%)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  11. PV-10 (rose bengal disodium, 10%)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Melanoma

    phase 1 small molecule completed

    1 trial

  12. PVSRIPO

    United Therapeutics Europe Ltd

    Invasive Breast Cancer

    phase 1 mab completed

    1 trial

  13. PYX-106

    Pyxis Oncology

    Solid Tumor

    phase 1 small molecule active

    1 trial

  14. PYX-201

    Pyxis Oncology

    Solid Tumor

    phase 1 small molecule active

    1 trial

  15. Paclitaxel

    Hospital Authority, Hong Kong

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  16. Paclitaxel

    Jazz Pharmaceuticals Ireland Limited

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  17. Palazestrant

    Olema Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  18. Panobinostat (LBH589), Carboplatin and Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  19. Part 1 TPST-1120

    Tempest Therapeutics

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  20. Part A: Dose Escalation of Cantrixil

    KAZIA THERAPEUTICS LTD

    Ovarian Neoplasms

    phase 1 small molecule completed

    1 trial

  21. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  22. Pegfilgrastim

    Biotech Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  23. Pelareorep

    ONCOLYTICS BIOTECH INC

    Breast Cancer

    phase 1 mab terminated

    1 trial

  24. Pembrolizumab

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  25. Pembrolizumab

    Cardiff Oncology

    Anal Cancer Stage III A

    phase 1 small molecule active

    1 trial

  26. Pembrolizumab

    United Therapeutics Europe Ltd

    Cervix Cancer

    phase 1 other terminated

    1 trial

  27. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  28. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  29. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  30. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  31. Pevonedistat

    Takeda

    Refractory Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

  32. Pevonedistat

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  33. Pevonedistat 25 mg/m^2

    Takeda

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  34. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  35. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  36. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  37. Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  38. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  39. Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

    Immunocore Ireland Limited

    Advanced PRAME Positive Cancers

    phase 1 other active

    1 trial

  40. Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

    Janssen-Cilag International N.V.

    Metastatic colorectal cancer and Gastric cancer

    phase 1 other active

    1 trial

  41. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema Pharmaceuticals

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  42. Phase 1 Study of PYX-106 in Solid Tumors

    Pyxis Oncology

    Solid Tumors

    phase 1 other active

    1 trial

  43. Phase 1 Study of PYX-201 in Solid Tumors

    Pyxis Oncology

    Advanced solid tumors

    phase 1 other active

    1 trial

  44. Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  45. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  46. Phase 1 trial of valemetostat and darolutamide in mCRPC

    Daiichi Sankyo

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  47. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  48. Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.